ArticleCancer medicine2020

Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.

Andrea S Fung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.